Jessica Jensen

Chief Tech/Sci/R&D Officer at POINT Biopharma, Inc. (United States)

44 year

Health Technology

Consumer Services

Commercial Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Joe McCann	M	47	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	5 years
Neil Fleshner	M	60	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	5 years
Allan Silber	M	75	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	5 years
Ari Shomair	M	-	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
William Demers	M	66	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 years
Gerald Hogue	M	66	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 years
Justyna Kelly	F	39	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	3 years
David Mims	M	60	PROGENICS PHARMACEUTICALS, INC.	5 years
Jonathan Goodman	M	56	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 years
Margaret Gilmour	F	64	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 years
Philip Johnson	M	59	POIT BIOP	1 years
Michael Gottlieb	M	45	POIT BIOP POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	4 years
Michael Thompson	M	-	POIT BIOP	1 years
Gerry Hogue	M	-	POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
Peggy Gilmour	F	-	POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
Howard M. Glase	M	-	POINT Biopharma, Inc. (United States) POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.	-
Gordon Brooks	M	-	POIT BIOP	1 years
Chris Anderson	M	-	POIT BIOP	1 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Mark Robert Baker	M	69	PROGENICS PHARMACEUTICALS, INC.	14 years
Peter J. Crowley	M	65	PROGENICS PHARMACEUTICALS, INC.	10 years
Angelo William Lovallo	M	59	PROGENICS PHARMACEUTICALS, INC.	7 years
Nicole S. Williams	F	79	PROGENICS PHARMACEUTICALS, INC.	12 years
Patrick Fabbio	M	56	PROGENICS PHARMACEUTICALS, INC.	5 years
Rajesh K. Malik	M	65	POIT BIOP	2 years
Bridget Martell	M	58	POIT BIOP	-
Karen Ferrante	M	66	PROGENICS PHARMACEUTICALS, INC.	6 years
Bradley Campbell	M	48	PROGENICS PHARMACEUTICALS, INC.	4 years
Mary Heino	F	64	PROGENICS PHARMACEUTICALS, INC.	-
Yael Margolin	M	70	POIT BIOP	2 years
David Lubner	M	60	POIT BIOP	2 years
Ann MacDougall	F	70	PROGENICS PHARMACEUTICALS, INC.	1 years
Michael Kishbauch	M	75	PROGENICS PHARMACEUTICALS, INC.	6 years
Robert J. Israel	M	67	PROGENICS PHARMACEUTICALS, INC.	21 years
David Scheinberg	M	68	PROGENICS PHARMACEUTICALS, INC.	25 years
Jeffrey D. Summer	M	64	PROGENICS PHARMACEUTICALS, INC.	3 years
Robin Hallett	M	-	POIT BIOP	-
Thomas Strack	M	-	PROGENICS PHARMACEUTICALS, INC.	-
Sherin Al-Safadi	M	-	POIT BIOP	-
Myra Rosario Herrle	M	-	POIT BIOP	2 years
Syed Mahmood	M	-	PROGENICS PHARMACEUTICALS, INC.	-
Daniel Pearlstein	M	-	POIT BIOP	2 years
Aseem Anand	M	-	PROGENICS PHARMACEUTICALS, INC.	-
Chris Horvath	M	-	POIT BIOP	1 years
Donna Husack	F	-	POIT BIOP	3 years
Hagop Youssoufian	M	67	PROGENICS PHARMACEUTICALS, INC.	1 years
Bryce V. Tenbarge	M	51	PROGENICS PHARMACEUTICALS, INC.	-
Asha Das	M	59	PROGENICS PHARMACEUTICALS, INC.	-
Robert Marshall	M	57	PROGENICS PHARMACEUTICALS, INC.	-
Matthew Vincent	M	-	POIT BIOP	1 years
Heinz Christoph Mäusli	M	61	PROGENICS PHARMACEUTICALS, INC.	1 years
Gérard Ber	M	66	PROGENICS PHARMACEUTICALS, INC.	1 years
Nitya G. Ray	M	71	PROGENICS PHARMACEUTICALS, INC.	17 years
Sheldon Hirt	M	60	PROGENICS PHARMACEUTICALS, INC.	1 years
Eric Ende	M	55	PROGENICS PHARMACEUTICALS, INC.	1 years
Melita Sequeira	F	-	POIT BIOP	-

Statistics

Country	Connections	% of total
United States	55	100.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections